Hyperion Therapeutics, Inc.

Robbins LLP Is Investigating the Officers and Directors of Hyperion Therapeutics, Inc. (HPTX) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Hyperion Therapeutics, Inc. (NasdaqGS: HPTX) breached their fiduciary duties to shareholders. Hyperion is a commercial biopharmaceutical company focused on the development and commercialization of therapeutics to treat disorders affecting the liver, gallbladder, biliary tree, pancreas, as well as orphan diseases.

Hyperion Announces Collusion between Andromeda Biotech, Ltd. Employees and Third-Party Biostatistics Firm

On September 8, 2014, Hyperion revealed that it is terminating the development of DiaPep277, used for treating newly diagnosed Type 1 diabetes patients, due to misconduct by recently acquired, Andromeda Biotech, Ltd. employees. Hyperion announced that it had uncovered evidence that indicates certain Andromeda employees colluded with a third party biostatistics firm to share and examine un-blinded data from the DIA-AID 1 and the ongoing DIA-AID 2 trial. Andromeda employees then used this shared data to manipulate the analyses to obtain favorable results in the DIA-AID 1 trial.

Hyperion Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

Send us a message for more information.

Protect your investments.

Sign up for free investment monitoring.

Stock Watch members receive free investment monitoring and notifications.  

Leave your details to get started